Parkinson’s Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature

Das, Biswadeep; Dash, Sriya Priyadarshini; Mohanty, Sasmita; Patel, Paritosh

doi:10.1007/978-3-030-55035-6_4

Cited by 4 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main pathological changes are the degeneration and loss of dopaminergic neurons in the substantia nigra and the formation of lewy bodies (Lv et al, 2021). (Das et al, 2021). Currently, there is still a lack of clear indicators for early diagnosis of PD, and the specificity for early diagnosis of PD is not high according to clinical symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…Motor symptoms include static tremor, myotonia, bradykinesia, and balance disorders. Non-motor symptoms include autonomic nervous dysfunction, sleep disorders, and depression ( Das et al, 2021 ). Currently, there is still a lack of clear indicators for early diagnosis of PD, and the specificity for early diagnosis of PD is not high according to clinical symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating CircRNAs Panel Acts as a Biomarker for the Early Diagnosis and Severity of Parkinson’s Disease

Zhong

Chen

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a chronic and progressive degenerative disease of the central nervous system. Degenerative neuropathy can occur in patients with PD even before typical clinical symptoms appear in the preclinical stage. Therefore, if the early diagnosis of degenerative diseases can be timely and the correlation with the disease progression can be explored, the disease progression will be slowed down and the quality of life of patients will be improved. In this study, the circRNA microarray was employed to screen the dysregulated circRNA in plasma samples of PD. Four circRNAs (circ_0085869, circ_0004381, circ_0017204, and circ_0090668) were obtained with increased levels in PD patients by cross comparison and preliminary verification in PD comparing with healthy controls. Further validation found the circRNA panel was consistent with the training set. The ROC curve also revealed a high diagnostic ability of circ_0004381 and circ_0017204 in predicting the early stage of PD from healthy controls. circ_0085869, circ_0004381, circ_0017204, and circ_0090668 also presented a high ability to distinguish the late stage of PD from early stage. In conclusion, circulating circRNA panel might be a potential fingerprint for predicting the early diagnosis of PD and may act as a biomarker for disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%